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meta-analysis
Dyani Lewis1, Danielle C Newton1, Rebecca J Guy2, Hammad Ali2, Marcus Y Chen1,3, Christopher K Fairley1,3
and Jane S Hocking1*Abstract
Background: Chlamydia trachomatis is a common sexually transmitted infection in Australia. This report aims to
measure the burden of chlamydia infection by systematically reviewing reports on prevalence in Australian
populations.
Methods: Electronic databases and conference websites were searched from 1997–2011 using the terms
‘Chlamydia trachomatis’ OR ‘chlamydia’ AND ‘prevalence’ OR ‘epidemiology’ AND ‘Australia’. Reference lists were
checked and researchers contacted for additional literature. Studies were categorised by setting and participants,
and meta-analysis conducted to determine pooled prevalence estimates for each category.
Results: Seventy-six studies met the inclusion criteria for the review. There was a high level of heterogeneity
between studies; however, there was a trend towards higher chlamydia prevalence in younger populations,
Indigenous Australians, and those attending sexual health centres. In community or general practice settings,
pooled prevalence for women <25 years in studies conducted post-2005 was 5.0% (95% CI: 3.1, 6.9; five studies),
and for men <30 years over the entire review period was 3.9% (95% CI: 2.7, 5.1; six studies). For young Australians
aged <25 years attending sexual health, family planning or youth clinics, estimated prevalence was 6.2% (95% CI:
5.1, 7.4; 10 studies) for women and 10.2% (95% CI: 9.5, 10.9; five studies) for men. Other key findings include pooled
prevalence estimates of 22.1% (95% CI: 19.0, 25.3; three studies) for Indigenous women <25 years, 14.6% (95% CI:
11.5, 17.8; three studies) for Indigenous men <25 years, and 5.6% (95% CI: 4.8, 6.3; 11 studies) for rectal infection in
men who have sex with men. Several studies failed to report basic demographic details such as sex and age, and
were therefore excluded from the analysis.
Conclusions: Chlamydia trachomatis infections are a significant health burden in Australia; however, accurate
estimation of chlamydia prevalence in Australian sub-populations is limited by heterogeneity within surveyed
populations, and variations in sampling methodologies and data reporting. There is a need for more large,
population-based studies and prospective cohort studies to compliment mandatory notification data.
Keywords: Chlamydia, Meta-analysis, Prevalence, Systematic review* Correspondence: j.hocking@unimelb.edu.au
1School of Population Health, University of Melbourne, Carlton, Victoria,
Australia
Full list of author information is available at the end of the article
© 2012 Lewis et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lewis et al. BMC Infectious Diseases 2012, 12:113 Page 2 of 18
http://www.biomedcentral.com/1471-2334/12/113Background
Chlamydia trachomatis (here after referred to as chla-
mydia) is the most commonly diagnosed bacterial sexually
transmitted infection (STI) in Australia [1,2]. In women,
chlamydia can lead to serious and costly health conse-
quences, particularly if the infection ascends from the endo-
cervix to the upper genital tract and causes pelvic
inflammatory disease (PID), which may result in fallopian
tube scarring, ectopic pregnancy, tubal infertility and
chronic pelvic pain [3-6]. Chlamydia also causes
epididymo-orchitis in men [7,8] and can act as a co-factor
in increasing the risk of HIV transmission in both men and
women [9].
Genital chlamydial infection became a notifiable dis-
ease in 1991 in all Australian States and Territories
except for NSW, which introduced mandatory notifica-
tion in 1997 [1]. Notification rates have been steadily
rising over the past decade [2], with rates highest
among young people. Chlamydia notification rates are
highest in the Northern Territory [2], which records
high rates among Indigenous Australians [10]. Given
that chlamydia is asymptomatic in up to 90% of infec-
tions, testing rates remain low (less than 10% in the
younger age groups) [11], and re-infections are com-
mon, notification data greatly underestimate the true
burden of infection. It is therefore important to gather
high quality, region-specific epidemiological data to es-
timate the prevalence of chlamydia in Australian popu-
lations. A review published in 2005 reported an overall
prevalence of chlamydia of 4.6% (95%CI: 4.4%, 4.8%)
[12]; however, there has been considerable further
chlamydia epidemiological research conducted in Aus-
tralia since then. This review examines the available
data on the prevalence of chlamydia across Australia
and provides an up-to-date picture of the burden of
chlamydia in Australian communities. This information
will help to inform future clinical practice and screen-
ing policies.Methods
Review strategy
The electronic bibliographic database Medline was
searched for English-language articles published between
1997 and July 2011. Reference lists of selected studies
were also checked for other potentially relevant studies.
Proceedings of the Australian Sexual Health Conference
were also reviewed to identify potential unpublished
studies. The PRISMA statement for preferred reporting
of systematic reviews and meta-analyses was used as a
guide to conducting the review and analysis [13].
The following search terms were used: (Chlamydia
trachomatis OR chlamydia) AND (prevalence OR epi-
demiology) AND Australia.The studies were reviewed and information extracted by
two authors independently; disagreements were resolved
by discussion and consensus. Criteria for inclusion were:
 Individuals were tested during the review period,
1997 to July 2011;
 The study presented the number of infections and
the total number of individuals tested;
 Nucleic acid amplification tests (NAAT) were used.
Studies were excluded for the following reasons:
 The study described self-reported STI diagnoses;
 Tests other the NAAT were used [14];
 The type of test was not specified and testing was
performed prior to 2000.
Studies conducted partially within the review period
were included if year-by-year data was presented, or if
the time was substantially within the review period and
NAAT testing was used throughout.
Variables extracted from each study included geographical
location, year of the study, setting, participants, specimen
type, gender, number of participants and number testing
positive. Where possible, the age (mean or range), participa-
tion rates, and age- and sex-specific prevalence data were
also extracted. For studies that did not report them, 95%
confidence intervals (CI) were calculated using exact meth-
ods in STATA 11 (StataCorp, College Station, TX, USA).
Results were classified by setting and participants, with
studies grouped into the following categories: general prac-
tice (GP) or community-based populations; clients of sex-
ual health, and family planning centres, youth centres, and
other medical clinics; pregnant women; Indigenous Austra-
lians; men who have sex with men (MSM); and high-risk
populations. Chlamydia positivity (number testing positive
divided by total number tested) was used as a surrogate
measure of chlamydia prevalence and on this basis, the
term ‘prevalence’ will be used throughout this review.
Meta-analysis
Where appropriate and where data was available, female and
male data were pooled separately for meta-analysis (STATA
11; StataCorp, College Station, TX, USA). Studies reporting
combined prevalence data for male and female participants
were excluded from meta-analysis. The I2 test was used to
estimate the proportion of total variability in point estimates
attributed to heterogeneity other than that due to chance.
Data were pooled according to the level of between-study
heterogeneity, using the following strategy [15]:
 I2 < 25%, fixed effects meta-analysis to estimate the
common prevalence (95% CI), assuming that all or
most between-study variability is due to chance;
Lewis et al. BMC Infectious Diseases 2012, 12:113 Page 3 of 18
http://www.biomedcentral.com/1471-2334/12/113 I2 25–75%, random effects meta-analysis to estimate
the average prevalence (95% CI);
 I2 > 75%, heterogeneity too great for summary
estimate to be calculated.
Possible reasons for heterogeneity were explored by
stratifying results by study setting.
Results
A total of 76 studies, described in 78 published articles
and six conference abstracts, from 129 articles and 48
abstracts fit the inclusion criteria (Figure 1; Table 1; Add-
itional files 1, 2, 3, 4, and 5). The majority of studies
(49 of 76) estimated chlamydia prevalence through cross-
sectional surveys, with sample sizes of between 44 and
2817 participants (median 346). There were also 19Medline
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Figure 1 Systematic review of chlamydia prevalence in Australian pop
literature review.clinical audits (median sample size 505; range 80–
26,097), three cohort studies (median 457; range 456–
1642), three sentinel surveillance reports (median 30,516;
range 3551–69,927), and two randomised controlled trials
(RCTs; mean 1218; range 843–1593).
Where both male and female participants were
included (30 studies), a substantial portion (16 studies)
did not report these data separately, or failed to report
by sex for some categories. These data were excluded
from further meta-analysis.
Where reported, the most commonly utilised sample
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Table 1 Studies reporting chlamydia prevalence data, identified in general practice or community settings
Study Location Participants Study
design
Specimen type Response
rate (%)
Sex Age
(years)
Study
period
Tested
(n)
Positive
(n)
Prevalence %
(95% CI)
General Population
Hocking [16] VIC (Melb) Women recruited from
the telephone directory
Cross-sectional
survey
Urine 43 F 18–35 2003–2004 657 6 0.9 (0.3, 2.0)
(18–24) 135 5 3.7 (1.2, 8.4)
(25–35) 489 1 0.2 (0.0, 1.1)
Community
Debattista [17] QLD (Bris) University students at
residential colleges
Cross-sectional
survey
Urine 30–50 F <25 1997 178 2 1.1 (0.1, 4.0)*
M 96 0 0 (0.0, 3.8)*
Debattista [18] QLD (Bris) High school students Cross-sectional
survey
Urine 30–50 F 15–18 1998–2001 516 12 2.3 (1.2, 4.0)**
M (1998) 170 2 1.2 (0.2, 4.6)*
(1999) 147 5 3.4 (1.3, 8.2)*
(2000) 101 0 0 (0.0, 4.6)*
(2001) 98 5 5.1 (1.9, 12.1)*
1998–2001 658 3 0.5 (0.1, 1.3)**
(1998) 339 0 0 (0.0, 1.4)*
(1999) 132 1 0.8 (0.0, 4.8)*
(2000) 94 0 0 (0.0, 4.9)*
(2001) 93 2 2.2 (0.4, 8.3)*
Bowden [19] ACT High school students Cross-sectional
survey
F: urine/ swab 31 F 15–20 2002–2003 273 2 0.7 (0.1, 2.6)
M 179 3 1.7 (0.3, 4.8)M: urine
Davis [20] ACT Tertiary students
recruited at outreach
screening services
Clinical outreach
pilot
Urine 29.4 M/F 16–26 2007 445 8 1.8 (0.1, 3.5)*
Gold [21] VIC
(rural/ regional)
Men attending rural
football clubs
Cross-sectional
survey
Urine 85 M 16–29 2006–2007 77 3 3.9 (0.8, 11.0)
Wade [22] VIC (Melb) Heterosexual men
attending sporting clubs
Cross-sectional
survey
Urine 87 M 16–29 n.r. 47 4 8.5 (2.4, 20.4)**
Buhrer-Skinner
[23]
QLD
(Towns-ville)
Individuals attending
outreach screening
services set up in a
variety of community locations
Cross-sectional
survey
M: urine n.r. M/F 21A 2004–2005 303 15 5.0 (2.8, 8.0)*
F: urine/ swab (M) 25 75 5 Army: 6.7
(2.2, 14.9)
(M/F) 21 95 5 University: 5.3
(1.7, 11.9)
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Table 1 Studies reporting chlamydia prevalence data, identified in general practice or community settings (Continued)
(M/F) 17 68 0 High school
festivities:
0 (0, 5.3)
(M/F) 25 65 5 Backpackers:
7.7 (2.5, 17.0)
Kong [24];
Kong [25]
VIC
(rural/ regional)
Young people
attending
sporting clubs
Cross-sectional
survey
Urine >95 F 16–29 2007 121 9 7.4 (3.5, 13.7)**
M 426 19 4.5 (2.7, 6.9)
Sacks-Davis [26] VIC (Melb) Young people
attending a
music festival
Cross-sectional
survey
Urine 21 F 16–29 2009 46 0 0 (0.0, 7.7)*
M 21 1 4.8 (0.1, 23.8)*
Davies [27] NSW (Sydney) Young
international
backpackers
recruited
at hostels
Cross-sectional
survey
F: swab 45.7 F 18–30 2009 207 8 3.9 (1.7, 7.5)
M: urine 50.2 M (≤25) 166 5 3.0 (1.0, 6.9)*
(26–30) 41 3 7.3 (1.5, 19.9)*
18–30 225 7 3.1 (1.3, 6.3)
(≤25) 164 6 3.7 (1.4, 7.8)*
(26–30) 61 1 1.6 (0.4, 8.8)*
General Practice
Heal [28] QLD (Mackay) Young people attending
general practices
Cross-sectional
survey
Urine 68 F/M 18–24 2001 443 17 3.8 (2.3, 6.1)*
Chiang [29] VIC (rural) Women attending
general practices
Cross-sectional
survey
Swab n.d. F 15–35 n.r. 67 9 13.4 (6.3, 24.0)*
Toyne [30] ACT Women attending
general practices
Cross-sectional
survey
Swab n.d. F 17–39 2002–2003 353 4 1.1 (0.3, 2.9)
Bowden [31] ACT Women attending
general practices
Cluster randomised
controlled trial
Swab/ urine 6.9 in intervention;
4.5 in control
F 16–39 2004–2005 1593 69 4.3 (3.4, 5.5)
(16–19) 196 10 5.1 (2.5, 9.2)
(20–25) 576 37 6.4 (4.6, 8.7)
(26–30) 425 19 4.5 (2.7, 6.9)
(31–39) 396 3 0.7 (0.2, 2.2)
Hince [32] WA (Perth) Men attending
general practices
Cross-sectional
survey
Urine 63–100 M 15–29 2007–2008 383 14 3.7 (2.0, 6.1)**
Bilardi [33] VIC (urban
and rural)
Women attending
general practices
Cluster randomised
controlled trial
Any 6.2–11.5 F 16–24 2008–2009 843 66 7.8 (6.1, 9.9)*
Walker [34] Australia-wide Women attending
primary health care
clinics
Cross-sectional
survey
Swab 66 F 16–25 2007–2008 738 25 3.4 (1.5, 5.3)
Studies are presented in order of publication year and author. * Confidence intervals calculated by authors. ** Re-calculated confidence intervals differ from those reported. A Median. ACT, Australian Capital Territory;
Bris, Brisbane; F, female; GP, general practice, general practitioner; M, male; Melb, Melbourne; NA, not applicable; n.d., not determined; n.r., not reported; NSW, New South Wales; QLD, Queensland; VIC, Victoria; WA,
Western Australia. Participant numbers reflect numbers from which epidemiological data was calculated, with sub-group numbers (e.g. by age or year) in brackets.
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<25
Hocking (2006) [16]
Bowden (2008) [31]
Bilardi (2010) [33]
Davies (2011) [27]
Walker (2011) [34]
(I2 = 73.3%, p = 0.005)
Random effects
3.70 (1.20, 8.40)
6.09 (4.30, 7.30)
7.83 (6.11, 9.85)
3.01 (0.98, 6.89)
3.39 (1.50, 5.30)
5.02 (3.14, 6.91)
All ages
Chiang (2006) [29]
Hocking (2006) [16]
Toyne (2006) [30]
Bowden (2008) [31]
Kong (2009; 2010) [24,25]
Sacks-Davis (2010) [26]
Davies (2011) [27]
Bilardi (2010) [33]
Walker (2011) [34]
(I2 = 89.6%, p = 0.000)
13.43 (6.30, 24.00)
0.91 (0.25, 1.77)
1.13 (0.30, 2.90)
4.33 (3.38, 5.45)
7.44 (3.46, 13.65)
0.00 (0.00, 7.71)
3.86 (1.68, 7.47)
7.83 (6.11, 9.85)
3.39 (1.50, 5.30)
 Study ID Prevalence (95% CI)
0 2 4 6 810 14 18 22 26
All ages
Buhrer-Skinner (2009) [23]
Gold (2007) [21]
Wade (2007) [22]
Kong (2009; 2010) [24,25]
Hince (2009) [32]
Sacks-Davis (2010) [26]
Davies (2011) [27]
Fixed effects (I2 = 0.0%, p = 0.876)
6.67 (2.20, 14.87)
3.90 (0.81, 10.97)
8.51 (2.37, 20.38)
4.46 (2.71, 6.88)
3.66 (2.00, 6.10)
4.76 (0.12, 23.82)
3.11 (1.23, 6.30)
4.01 (2.82, 5.20)
A
B Study ID Prevalence (95% CI)
0 2 4 6 810 14 18 22 26
<30
Gold (2007) [21]
Wade (2007) [22]
Hince (2009) [32]
Kong (2009; 2010) [24,25]
Sacks-Davis (2010) [26]
Davies (2011) [27]
Fixed effects (I2 = 0.0%, p = 0.885)
3.90 (0.81, 10.97)
8.51 (2.37, 20.38)
3.66 (2.00, 6.10)
4.46 (2.71, 6.88)
4.76 (0.12, 23.82)
3.11 (1.23, 6.30)
3.92 (2.71, 5.13)
Figure 2 Chlamydia in general practice and community settings. Meta-analysis of chlamydia prevalence estimated in general practice and
community settings. A. Females. B. Males.
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Eighteen studies (18 papers; 1 abstract) reported on chla-
mydia prevalence estimates from studies conducted in GP
or community-based settings (Table 1) [16-34]. Seven
reported on prevalence measured in GP clinics [28-34],
while other studies recruited participants from
community-based settings including sporting clubs (3)
[21,22,24,25], university or high school campuses (5) [17-
20,23], festivals (2) [23,26], backpacker hostels (2) [23,27],
and a defense force unit (1) [23]. Only one study utilised a
population-based sample of young women recruited from
a telephone directory [16]. Participation rates were highest
(>80%) in studies conducted in sporting clubs
[21,22,24,25], and lowest in two GP-based RCTs of chla-
mydia testing interventions (<11.5%) [31,33].In community-based settings, reported prevalence
estimates were 3.9–8.5% for men and 7.4% for women
recruited from sporting clubs [21,22,24,25], 3.5–7.7%
among male and female backpackers [23,27], and 0.0–
5.3% for young people in educational settings [17-
20,23]. The only population-based study reported a
prevalence of 3.7% among sexually active 18–24-year-
old women [16], with no population-based data avail-
able for men.
In general practice, chlamydia prevalence for women
ranged from 1.1–13.4%, although the highest and lowest
estimates were from studies with either a small sample
size [29], or a higher proportion of older women [29].
The most recent cross-sectional surveys, one in men [32]
and one in women [34], had similar participation rates of
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males and females (3.7% and 3.4%, respectively). Preva-
lence was higher in the two RCTs, at 5.1–7.8% among
women aged 16–25 years; however, response rates were
low (<11.5%).
The majority of GP and community-based studies (14)
provided prevalence estimates for those aged 30 years or
less, with nine studies providing estimates for those aged
25 years or less, and just three providing age-stratifiedAll ages
Debattista (2002) [18]
Donovan (2002) [36]
Williams (2003) [37]
Cole (2004) [50]
Debattista (2004) [54]
Jones (2004) [51]
Hocking (2005; 2006) [38,39]
Bateson (2006) [40]
Petersen (2007) [55]
Buhrer-Skinner (2009) [23]
McIver (2009) [42]
O’Rourke (2009) [43]
Franklin (2010) [44]
Goller (2010) [45]
Guy (2011) [46]
McKechnie (2011) [47]
Walker (2011) [34]
(I2 = 98.8%, p = 0.000)
<25
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Hocking (2005; 2006) [38,39]
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Petersen (2007) [55]
O’Rourke (2009) [43]
Franklin (2010) [44]
Goller (2010) [45]
McKechnie (2011) [47]
Walker (2011) [34]
(I2 = 69.5%, p = 0.000)
Random effects
A Study ID
0
All ages
Bowden (1998) [35]
Debattista (2002) [18]
Donovan (2002) [36]
Cole (2004) [50]
Jones (2004) [51]
Hocking (2005; 2006) [38,39]
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Jones (2004) [51]
Hocking (2005; 2006) [38,39]
Franklin (2010) [44]
Goller (2010) [45]
Vodstrcil (2011) [48]
Fixed effects (I2 = 0.0%, p = 0.684)
B Study ID
0
Figure 3 Chlamydia in sexual health clinics, youth services and other
sexual health clinics, youth services and other clinical settings. A. Females.data [16,27,31]. For women, one clinic-based [31] and
one community-based study [16] reported higher preva-
lence among women under 25 years, compared with
older women: 6.1% and 3.7% versus 5.5% and 1.7%, re-
spectively. A third study measured prevalence in both
male and female International backpackers [27] and
reported a higher chlamydia prevalence in women aged
over 25 years (7.3%), compared with younger women
(3.0%); with the trend reversed in men (1.6% versus10.60 (3.50, 23.10)
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with no trend evident [18].
Pooled prevalence estimates for women aged <25 years
or for women of any age group could not be calculated
due to significant heterogeneity between studies
(I2 > 75%, p < 0.01). However, if studies conducted prior
to 2006 were excluded, the pooled prevalence of women
aged <25 years was 5.0% (CI: 3.1, 6.9; I2 = 73%, p < 0.01)
(Figure 2A) and if the two RCTs with low response rates
were excluded [31,33], the pooled prevalence for under
25 year old women was 3.3% (CI: 1.9, 4.8; I2 = 0%,
p = 0.96) and 2.6% (CI: 1.0, 4.1; I2 = 72%, p < 0.01) for
women of all ages. For men, a pooled estimate of 3.9%
(CI: 2.7, 5.1; I2 = 0%, p = 0.88) was calculated for men
aged <30 years and 4.0% (CI: 2.8, 5.2; I2 = 0%, p = 0.88)
for all ages (Figure 2B). There was only one study for
<25-year-old men conducted in the period from 2006
onward and this reported a prevalence of 3.7% (CI: 0.4,
6.9) [27]; all studies for men <30 years were conducted
post-2005. Pooled estimates by setting were not calcu-
lated because of significant heterogeneity between stud-
ies (I2 >75%, p < 0.01). However, if studies conducted
prior to 2006 and the two RCTs with low response rates
were excluded, the pooled prevalence was higher in GP
clinics than in community-based studies (3.5%; CI: 2.1,
4.9; I2 = 0%, p = 0.85, versus 2.9%; CI: 2.0, 3.8; I2 = 0%,
p = 0.47).
Sexual health centres, youth health services and other
clinical settings
There were 24 studies (23 papers; 2 abstracts) reporting
chlamydia prevalence estimates in clients attending sex-
ual health or family planning clinics (14 studies) [34-48],
youth centres (8) [18,23,28,45,49-53] and other clinical
settings (4) [45,54-56] (Additional file 1).
For studies conducted at sexual health clinics, the ma-
jority (7) were retrospective audits of patient records
[36,38,39,41,43,44,48,57], five were cross-sectional sur-
veys [34,37,40,42,47] and two were sentinel surveillance
reports [45,46]. Sample sizes varied greatly, from 175
[42] to 59,720 [46]. Six studies provided estimates for
women only [34,37,40,42,43,47], three for men only
[35,41,48], and four for both males and females
[36,38,39,45,46]; one study did not differentiate between
males and females [44]. Prevalence estimate ranges were
5.3–13.4% for males and 0.6–13.0% for females, although
the study with a prevalence of 0.6% excluded women
<18 years and those with pelvic inflammatory disease
[42]. Where age-stratified estimates were available,
prevalence tended to be highest among those <25 years
for both males and females [37-39,43,47,48].
Three studies reported on prevalence trends over time
in sexual health clinics [43,44,48]. Two comprehensive
analyses found that chlamydia prevalence increased byabout 12% per year (from 4.2% in 2003 to 6.7% in 2007)
among females [43] and by 3% per year (from 5.8% in
2002 to 8.0% in 2009) among heterosexual males [48]
after adjusting for changes in patient demographics, clin-
ical presentation or sexual behaviour over time.
Two cross-sectional surveys and one sentinel surveil-
lance study compared chlamydia prevalence in sexual
health and family planning clinics across multiple geo-
graphic locations. A study of women attending family
planning clinics found a higher prevalence at an inner
city clinic: 4.8% versus 1.7% at a suburban clinic [37].
Younger women (<25 years) attending the inner-city
clinic had a higher prevalence (6.2%), whereas the preva-
lence for this age group at the suburban clinic was 1.7%.
Similarly, higher prevalence estimates in inner-city
clinics compared with suburban clinics were reported by
Bateson and colleagues [40] (9.7% versus 3.1%).
For the eight studies that determined prevalence at
youth centres [23,28,45,49-53], prevalence estimates
ranged from 0–20.0%. One study reported increased
prevalence from one year to the next (2.7% in 2006/07
vs. 11.3% in 2007/08); however, the increase likely
reflected a change in the mode of operation from an
appointment-based to drop-in service [53]. Sample sizes
in this setting were also frequently low, and half did not
report data for males and females separately
[28,49,52,53].
In non-primary care clinical settings, the chlamydia
prevalence for women attending a colposcopy clinic was
reported to be higher in women aged 25 years or less
(5.8%) compared with older women (0.9%) [55]. A preva-
lence of just 0.2% was found for women attending a hos-
pital in vitro fertilisation (IVF) service for investigation
of infertility [54]; however, higher estimates for hospital-
based studies of 3.1% for women [45] and 5.5% for men
and women [56] were also reported. These divergent
estimates were possibly due to age differences in study
participants, although the precise age range of partici-
pants was not available for two of the studies [45,54].
Meta-analysis was performed for males and females
separately by age group (Figure 3). The pooled preva-
lence for women <25 years was 6.2% (CI: 5.1, 7.4;
I2 = 73%, p < 0.01). It was not possible to calculate the
pooled prevalence for women of all ages because of sig-
nificant heterogeneity between studies (I2 = 99%,
p < 0.01) (Figure 3A). When analysed by setting, there
was significant heterogeneity for studies conducted in
sexual health or family planning clinics, but for women
attending youth centres, the pooled prevalence was 6.8%
(CI: 3.8, 9.7; I2 = 0%, p = 0.51) for women <25 years and
7.0% (CI: 4.1, 9.9; I2 = 0%, p = 0.59) for women of all ages.
Within other clinical settings, the pooled prevalence was
2.1% (CI: 0.9, 3.4; I2 = 0%, p = 0.97) for women of all
ages.
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across all study sites was not calculated due to heterogen-
eity (I2 = 98.8%, p < 0.01); however, the pooled prevalence
was 10.2% (CI: 9.5, 10.9; I2 = 0%, p= 0.41) for men
<25 years (Figure 3B). In sexual health/family planning
clinics, the pooled prevalence was 9.9% (CI: 9.1, 10.8;
I2 = 0%, p = 0.45) for men <25 years; it was not possible to
calculate the pooled prevalence for men of all ages attend-
ing sexual health/family planning clinics because of signifi-
cant heterogeneity between studies (I2 = 99%, p < 0.01). In
youth centres, the pooled prevalence was 8.7% (CI: 0, 28.2;
I2 = 50%, p= 0.16) among men <25 years.
Pregnant women
Eleven studies (10 papers; 1 abstract) reported preva-
lence estimates in pregnant women, from a range of
urban and rural/remote locations (Additional file 2)
[58-68]. Sample sizes ranged from 70 [59] to 1175 [58]
participants, and participation rates in most studies were
high (52–99.8%).
Reported chlamydia prevalence estimates were diverse,
ranging from 2.8–14.4%, with prevalence highest among
young and/or Indigenous women. In studies with age-
stratified data, all reported higher prevalence estimates in
women <25 years (4.5–22.0%), compared with participants
of all ages (2.7–14.4%) [62-64]. Three studies of women
aged 20 years or younger reported estimates of 5.7–13.7%
[60,61,65], and three further studies where age was not
specified reported prevalence estimates of 2.8% [59], 3.9%
[66] and 12.3% [68]. A large study conducted in publicChen (2009) [67]
Cheney (2008) [65]
All ages
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Figure 4 Chlamydia in pregnant women. Meta-analysis of chlamydia prehospital antenatal clinics in Victoria reported a prevalence
of 3.2% among women <25 years [67].
For pregnant Indigenous women, rates of infection
ranged from 2.9–14.4% [59,63,64,68]. A comparison of
prevalence in Indigenous versus non-Indigenous women
reported higher estimates in Indigenous women: 9.1%
compared with 2.7% overall [64]. One study reporting
age-stratified data found a prevalence of 14.4% overall,
with higher prevalence in teenagers (32.6%) [63]. This is
also higher than the two hospital-based teen studies,
despite both having high proportions of Indigenous par-
ticipants: 30.3% [60] and 74.6% [61].
It was not possible to calculate pooled prevalence esti-
mates because of significant heterogeneity between the
studies (I2 = 89.5%, p < 0.01), which persisted when the
studies were stratified by age (<25 years, I2 = 88.6%,
p < 0.01; Figure 4).
Indigenous Australians
Prevalence estimates for Indigenous Australians were
reported in 16 reviewed studies (17 papers; 1 abstract)
[18,23,44,59,63,64,68-78] (Additional file 3). Sample sizes
varied from 20 [23] to 2817 [72] and while participation
rates were reported in only seven of the studies, four
cited rates of over 80%. The majority of studies were
conducted in rural or remote areas (5) [59,69,71-73,79]
or regional centres (6) [23,63,68,74,76-78]. Only three
studies were conducted in large capital cities [18,23,44],
and one sentinel surveillance study reported data from
both urban and rural locations [77].3.24 (1.80, 5.90)
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Figure 5 Chlamydia in Indigenous Australians. Meta-analysis of chlamydia prevalence estimated in Aboriginal and Torres Strait Islander
individuals. A. Females. B. Males.
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http://www.biomedcentral.com/1471-2334/12/113Estimates ranged from 4.8–14.4% for women, and 8.6–
16.3% for men. Three studies only reported combined
prevalence estimates for men and women (4.4–15%).
The highest reported estimates were in younger age
groups. Two studies reported age-stratified data, with
prevalence very high in both male and female teens
(males 13.0–18.8%; females 17.4–34.3%), and then de-
creasing with age [72,77]. A further study of Indigenous
youths reported high estimates of 21.0% for males and
11.8% for females aged 15–18 years [18]; while pregnant
Indigenous teens recorded prevalence estimates ranging
from 2.9% [59] to 32.6% [63].In studies that compared Indigenous with non-
Indigenous individuals, three of four studies reported
higher prevalence estimates for Indigenous study partici-
pants [23,63,64]. One study found that, when considered
separately, women identifying as Torres Strait Islanders
had a prevalence of 9.7%, whereas Aboriginal women
had a prevalence of just 3.5%, lower than for non-
Indigenous women in the study (3.8%) [63]. A single
study conducted in a large urban sexual health clinic
found a lower prevalence in Indigenous (6.7%) compared
with non-Indigenous clients (9.4%), although this was
not a significant difference [44].
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Figure 6 Chlamydia in men who have sex with men (MSM). Meta-analysis of chlamydia prevalence estimated in men who have sex with
men (MSM). A. Rectal. B. Urethral. C. Pharyngeal.
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[69,70], finding that prevalence decreased for both men
and women over the first study period (1998–2000),
from 8.8% to 7.2% in men, and from 9.1% to 7.2% in
women. However, this was linked to the introduction of
a sexual health intervention, and the falls were not sig-
nificant [69]. The odds of testing positive for chlamydia
decreased significantly by 12% per year (CI: 8, 16) be-
tween 1996 and 2002, but no further reduction was
observed between 2003 and 2006 [70].
Pooled prevalence estimates were higher for women
than for men and higher among those aged <25 years
(Figure 5). Among women, the pooled prevalence for
those <25 years was 22.1% (CI: 19.0, 25.3; I2 = 0%,
p = 0.96) and across all ages, 10.5% (CI: 8.6, 12.4;
I2 = 73%, p < 0.01). For men, the pooled prevalence for
<25-year-olds was 14.7% (CI: 11.5, 17.8; I2 = 0%, p = 0.61)
and across all ages, 8.6% (CI: 7.2, 10.0; I2 = 31%,
p = 0.22).
Men who have sex with men (MSM)
Sixteen studies (19 papers) were identified that measured
chlamydia prevalence in MSM [38,39,44-46,48,79-91]
(Additional file 4). Sample sizes ranged from 80 [82] to
11,777 [91], and settings included sexual health centres
(11 studies) [38,39,44-46,48,79,81,84,85,89-91], hospitals
and other clinical settings (3) [85,86,90], and male-only
entertainment or sex-on-premises venues (SOPVs; 4)
[79-81,83]. One study involved community-based cohorts
of HIV-positive and HIV-negative MSM [87,88]. Where
reported, participation rates were high in clinical settings
(77–85%), but much lower in SOPVs (24–50%).
Overall, 12 studies reported prevalence estimates for
urethral infection, 10 for rectal infection, and 10 for
pharyngeal infection, while five did not provide site-
specific estimates. The prevalence of rectal infection was
consistently more than 30% higher than urethral infec-
tion and ranged from 4.0% among HIV-positive men
attending HIV clinics [90] to 14.7% among men attend-
ing a sexual health clinic [84]. Urethral infection preva-
lence ranged from 1.0% [86] to 5.0% [84]. Estimates for
pharyngeal infection were low, ranging from 0.0% in
both clinical and SOPV settings [80,82,90] to 2.7% [85].
A large well-conducted cohort study found the preva-
lence of rectal and urethral chlamydia at the time of re-
cruitment to be higher among HIV-positive compared
with HIV-negative men (5.9% versus 4.4% and 0.9% ver-
sus 2.2%), although this was not statistically significant
[87,88].
The pooled prevalence for rectal chlamydia was 5.6%
(CI: 4.8, 6.3; I2 = 54%, p = 0.02) and was similar between
men tested in SOPVs (6.2%: CI: 4.3, 8.2; I2 = 0%, p = 0.49)
and in clinics (5.7%, CI: 4.7, 6.7; I2 = 61%, p = 0.01)
(Figure 6A). It was not possible to calculate an overallpooled prevalence for urethral chlamydia because of het-
erogeneity between studies (I2 = 86%, p < 0.01)
(Figure 6B). This was also the case for clinic-based ur-
ethral chlamydia prevalence (I2 = 80%, p < 0.01). The
pooled prevalence for urethral chlamydia among men
tested at SOPVs was 2.1% (CI: 1.0, 3.1; I2 = 0%, p = 0.44).
For pharyngeal chlamydia (Figure 6C), the pooled preva-
lence across settings was 0.5% (CI: 0.2, 0.9; I2 = 33%,
p = 0.14), and was similar between SOPVs (0.5%; CI: 0,
1.1; I2 = 0%, p = 0.53) and clinical settings (0.3%; CI: 0,
0.8; I2 = 23%, p = 0.26).
High-risk populations
Twelve papers were identified that estimated chlamydia
prevalence in potentially high-risk populations
[18,38,44,60,78,89,92-97] (Additional file 5). Five mea-
sured chlamydia prevalence in sex workers (legal and il-
legal) [38,44,92-94], four in individuals in prison or
juvenile detention [18,78,95,96], two in drug users
[60,97], and one in STI contacts [89]. Participation rates,
where reported, were high (49–87%), and sample sizes
varied from 86 [78] to 1766 [93].
Prevalence in sex workers ranged from 1.2–8.3%.
Three of the five studies did not differentiate between
male and female sex workers, although all had predom-
inantly female participants [38,92,93]. Brothel workers
had lower prevalence estimates in two studies, compared
with street sex workers [92,93]. However, a study of il-
legal brothel sex workers in Western Australia found a
low prevalence of 2.7% [94]. Two clinical audits con-
ducted at sexual health centres found divergent esti-
mates of 3.3% [38] and 7.8% [44] for female sex workers,
and 11.1% for male sex workers [44].
For prisoners, a study by Mak and colleagues [95]
reported that 3% of male prisoners tested positive for
chlamydia upon admission to prison. A larger study con-
ducted across male and female prisons in both metro-
politan and regional locations recorded an overall
prevalence of 7.3% [96]. For the juvenile detainees, chla-
mydia prevalence for females was measured at over 20
per cent in two separate studies [18,96], higher than for
male juveniles (range 2.0–16.3%).
In a sample of injecting drug users, 6% tested positive
for chlamydia [97]; and in pregnant teens, chlamydia
was more prevalent in multi-drug– (25.8%) and
marijuana-users (9.7%), compared with non-users (7.7%).
The highest prevalence (33.1%) was reported for clients
attending a sexual health centre as contacts of chla-
mydia, non-gonococcal urethritis and PID [89].
Discussion
We found that chlamydia prevalence estimates were
highly variable, with rates generally higher among young
Australians, Indigenous Australians, and MSM. Other
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pregnant teenagers and prison inmates, were also found
to have higher prevalence estimates. This review builds
considerably on the earlier review by Vajdic et al. [12],
and a key strength is that studies were limited to those
that used the more sensitive and specific NAAT testing
methods.
Measuring the true prevalence of chlamydia in a com-
munity is a challenging task, with non-population-based
studies frequently suffering from sampling bias and low
participation rates [98,99]. Studies utilising population-
based data on chlamydia prevalence are rare, both in
Australia and the UK [12,100], and this review identified
just one survey that recruited participants from the gen-
eral population. This study, of women recruited from
the telephone directory, was limited by its small sample
size and low participation rate (43%) [16]. Both
community-based and clinic-based sampling is subject
to participation bias: community-based sampling often
relies on convenience sampling, where participants are
able to self-select; and clinic-based sampling is likely to
bias towards symptomatic and higher risk participants,
and towards more health care–seeking, and therefore
well-educated, Australian-born participants [34]. This
can also be true of population-based studies [16]. Sexual
health centre studies can be particularly susceptible to
bias towards symptomatic and high-risk groups, al-
though as a research setting, they can provide large sam-
ple sizes at low costs, especially through clinic audits.
Community-based studies are important for estimating
chlamydia prevalence as notification rates are known to
under-estimate infection levels, as they are highly influ-
enced by testing rates. The only population-based esti-
mate identified in this review reported a prevalence of
3.1% among all 18 to 24 year old women in 2003–2004
[16]; no similar study has been conducted in men. This
would translate into over 10,500 cases of chlamydia
among Victorian women aged 15–24 years in 2004 (and
10,900 cases in men of the same age), which is consider-
ably higher than the 7694 cases notified among both
men and women of any age in Victoria that year [2],
highlighting that notification data considerably under-
estimate of the true number of individuals infected.
A key factor that limits the conclusions that can be
drawn from the studies included in the review is the
high level of heterogeneity both within and between the
populations studied. In most key populations reviewed,
pooled prevalence estimates could not be calculated,
even after stratifying data by age and sex of individuals
tested. This was particularly true for female data. Al-
though we calculated pooled prevalence estimates within
the different population sub-groups, it is important that
these be interpreted with caution and only indicative of
the true prevalence.The high level of variability between studies also pre-
vented prevalence trends over time to be assessed, des-
pite the review period spanning almost 15 years. Only
seven individual studies determined time trends
[18,36,43,44,48,69], three finding a statistically significant
increase in prevalence over time [36,43,48]; and two
reporting no change over time [18,44]. One study in an
Indigenous community found a decrease over time,
however, this was associated with an STI intervention to
increase testing rates [69]. Despite the variability, the
studies by Vodstrcil et al. [48] and O’Rourke et al. [43] –
both conducted in sexual health clinics – provide evi-
dence to support an increasing chlamydia prevalence
among heterosexual men and women in Australia, be-
cause these studies had large sample sizes and adjusted
for changes in sexual behaviour over time. Both Austra-
lian and international data show that sexual risk behav-
iour has changed over the last decade with increasing
numbers of sex partners reported by young adults. The
National Survey of Sexual Attitudes and Lifestyles, a sex-
ual behaviour survey conducted in the United Kingdom
in 1990 and again in 2000 [101] showed that the number
of heterosexual partners in the preceding five years
increased significantly for both sexes. Australian data
show that age at first sexual intercourse has decreased,
with women aged 16–24 years reporting a median age of
16 at first sexual intercourse compared with 19 for
women aged 50–59 years [102].
Similar to previous systematic reviews in both the UK
and Australia [12,100], we found that the study setting
influenced the prevalence estimates reported; however,
significant heterogeneity again hampered comparisons in
most cases. For men, prevalence was higher in sexual
health and family planning clinics compared with GP
and community-based settings. This was similar for
women aged <25 years; however, this difference was not
statistically significant. GP-based studies, similar to those
conducted by Vodstrcil et al. [48] and O’Rourke et al.
[43] in sexual health centres, would greatly enhance our
ability to compare between these clinical settings.
Between-setting comparisons are especially fraught for
men; only one study conducted in general practice
reported prevalence among men alone [32], and no stud-
ies reported chlamydia prevalence in heterosexual men
from a population-based sample.
Where studies reported age-based estimates, younger
participants had higher prevalence estimates than older
participants. These data are consistent with the national
notification data that show that notification rates are
highest among those <25 years [2] and are also consist-
ent with sexual behaviour data which show that numbers
of sexual partners are highest in these younger age
groups [103]. We also found high rates among disadvan-
taged youth and young people attending youth clinics.
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men and women echo those findings in overseas preva-
lence studies [98,99].
Chlamydia notification rates over the past 15 years
have been consistently higher in women compared with
men; however, this did not emerge as a robust trend in
this review. Higher female notification rates can prob-
ably be attributed to differences in chlamydia testing
rates. In Australia, recent Medicare data indicates that
about 12–13% of sexually active young women and 3–
4% of young men are tested for chlamydia each year
[11]. As chlamydia testing rates increase in Australia,
notification data will be able to provide a better estimate
of the population prevalence of chlamydia.
We found that prevalence estimates were comparable
among heterosexual men and women; however, the pic-
ture is neither complete nor consistent. In the general
practice setting, no studies directly compare prevalence
between men and women; and in sexual health clinics,
prevalence tended to be higher among men. This is
probably because men are more likely to attend a sexual
health centre due to the presence of urethral symptoms
[104]. Curiously, fifteen studies were identified that did
not report male and female data separately, thereby ex-
cluding the data from calculations of pooled prevalence
estimates. A number of recent studies reporting chla-
mydia prevalence in men attending sporting clubs
[21,22,24,25] and general practices [32] have started to
address the predominance of female studies, which has
been previously noted [12]; however, there remains a
need for additional studies that directly compare men
and women in community and clinical settings.
Similar discrepancies between notification data and
population-based prevalence surveys have also been ob-
served in the USA. In 2010, the notification rate reported
to the Centers for Disease Control and Prevention was
2.6 times higher for women (610.6 per 100,000 popula-
tion) than for men (233.7 per 100,000) [105]; rates in
2002 differed by almost four-fold between the sexes. By
comparison, prevalence estimates reported in the National
Health and Nutrition Examination Survey (NHANES)
conducted between 1999–2002 were similar in women
(2.5%; CI: 1.8, 3.4) and men (2.0%; CI: 1.6–2.5) [106]. Al-
though the prevalence was twice as high in women aged
14–19 years (4.6%) compared to men (2.3%), the trend
was reversed in the 20–29 year age group, where more
men were infected (3.2%) than women (1.9%) [106].
These data underscore the fact that at low testing rates,
notification data do not provide a full picture of the
prevalence of chlamydia infection in the community.
In contrast to heterosexual men, several studies
explored chlamydia prevalence among MSM, with most
providing estimates from multiple anatomical sites
(Additional file 4). In line with data from the UK andUSA [107,108], prevalence was highest in rectal swabs
compared with urethral samples, and lowest in
pharyngeal swabs. This highlights the importance of rec-
tal chlamydia screening in MSM and the need to include
both urethral and rectal sampling when conducting chla-
mydia prevalence surveys in this population group as
recommended in national guidelines [109]. Unfortu-
nately, Australian national notification data do not in-
clude site of infection nor sexual orientation, thereby
reducing our ability to monitor trends in this population
group over time.
The key gaps identified by Vajdic et al. [12] still remain
today, including a need for population-based data for
young men and women and systematically collected serial
sentinel data with which trends in chlamydia prevalence
over time can be monitored, particularly within the na-
tionally identified target risk groups (young men and
women, MSM and Indigenous Australians) [110]. The fur-
ther advances in information technology including
improvements in medical records software, the develop-
ment of data extraction software [111] and data linkage
[112], will facilitate the collection of standardised and
detailed socio-demographic, behavioural and clinical data
(including presence or absence of chlamydia-related
symptoms) from sentinel sites. This will allow trends to be
evaluated over time within different risk groups, adjusting
for any changes in behavioural data and clinical pre-
sentation. The Australian Collaboration for Chlamydia
Enhanced Sentinel Surveillance (ACCESS; www.access-
study.org) [44] and the Victorian Primary Care Network
for Sentinel Surveillance (VPCNSS) [45] are both import-
ant sentinel surveillance projects that collect detailed
demographic, clinical and behavioural data with which
trends in risk groups can be monitored over time. It is
vital that such surveillance systems continue to be funded.
Further, the Australian Chlamydia Control Effectiveness
Pilot (ACCEPt; www.accept.org.au), a randomised con-
trolled trial of chlamydia testing in general practice, is col-
lecting chlamydia testing data from about 250 GP clinics
across Victoria, New South Wales, Queensland and South
Australia and will provide trends in chlamydia positivity
over time among young men and women.
Conclusions
This comprehensive systematic review identified 76
studies reporting prevalence data for individuals tested
for anogenital or pharyngeal chlamydia and provides an
up-to-date summary of the underlying burden of chla-
mydia in Australian populations. The review highlights
that the burden of chlamydia in Australia is greatest
among young adults, Indigenous populations and MSM
and identifies important gaps in the surveillance and
monitoring of chlamydia infection in Australia. Given
that that the Australian Government is currently pilot
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State Governments continue to fund chlamydia control
activities, it is vital that good sentinel surveillance sys-
tems continue.Additional files
Additional file 1: Studies reporting chlamydia prevalence data,
identified in sexual health clinics, youth services and other clinical
settings. Studies are presented in order of publication year and author.
* Confidence intervals calculated by report authors. ** Re-calculated
confidence intervals differ from those reported. A Median. F, female; M,
male; Melb, Melbourne; NA, not applicable; n.d., not determined; n.r., not
reported; NSW, New South Wales; NT, Northern Territory; QLD,
Queensland; VIC, Victoria; WA, Western Australia. Participant numbers
reflect numbers from which epidemiological data was calculated, with
sub-group numbers (e.g. by age or year) in brackets.
Additional file 2: Studies reporting chlamydia prevalence data,
identified in pregnant women. Studies are presented in order of
publication year and author. * Confidence intervals calculated by authors.
** Re-calculated confidence intervals differ from those reported.
A Median. Melb, Melbourne; NA, not applicable; n.d., not determined; n.r.,
not reported; NSW, New South Wales; QLD, Queensland; VIC, Victoria; WA,
Western Australia. Participant numbers reflect numbers from which
epidemiological data was calculated, with sub-group numbers (e.g. by
age or year) in brackets.
Additional file 3: Studies reporting chlamydia prevalence data,
identified in Indigenous Australians. Studies are presented in order of
publication year and author. * Confidence intervals calculated by authors.
** Re-calculated confidence intervals differ from those reported.
A Median. Bris, Brisbane; F, female; GP, general practice, general
practitioner; M, male; Melb, Melbourne; NA, not applicable; n.d., not
determined; n.r., not reported; NSW, New South Wales; NT, Northern
Territory; QLD, Queensland; SA, South Australia; WA, Western Australia.
Participant numbers reflect numbers from which epidemiological data
was calculated, with sub-group numbers (e.g. by age or year) in brackets.
Additional file 4: Studies reporting chlamydia prevalence data,
identified in men who have sex with men. Studies are presented in
order of publication year and author. * Confidence intervals calculated by
report authors. ** Re-calculated confidence intervals differ from those
reported. A Median. ACT, Australian Capital Territory; HIV+, HIV-positive;
HIV–, HIV-negative; Melb, Melbourne; NA, not applicable; n.d., not
determined; n.r., not reported; NSW, New South Wales; Ph, Pharynx; QLD,
Queensland; R, rectum; SHC, sexual health centre; U, urethra; VIC, Victoria.
Participant numbers reflect numbers from which epidemiological data
was calculated, with sub-group numbers (e.g. by age or year) in brackets.
Additional file 5: Studies reporting chlamydia prevalence data,
identified in high-risk populations. Studies are presented in order of
publication year and author. * Confidence intervals calculated by authors.
** Re-calculated confidence intervals differ from those reported.
A Median. Bris, Brisbane; broth, brothel; CBD, central business district; F,
female; M, male; Melb, Melbourne; NA, not applicable; n.d., not
determined; n.r., not reported; NSW, New South Wales; QLD, Queensland;
st, street; WA, Western Australia. Participant numbers reflect numbers
from which epidemiological data was calculated, with sub-group
numbers (e.g. by age or year) in brackets.Abbreviations
ACT: Australian capital territory; Bris: Brisbane; CI: 95% confidence interval;
GP: General practice, general practitioner; Melb: Melbourne; MSM: Men who
have sex with men; NA: Not applicable; NAAT: Nucleic acid amplification test;
n.d.: Not determined; n.r.: Not reported; NSW: New South Wales;
NT: Northern Territory; PID: Pelvic inflammatory disease; QLD: Queensland;
SA: South Australia; SOPV: Sex on premises venue; VIC: Victoria; WA: Western
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